Abstract: The invention relates to certain 1,5-benzothiazepine and 1,2,5-benzothiadiazepine derivatives as defined herein. These compounds are bile acid modulators having apical sodium-dependent bile acid transporter (ASBT) and/or liver bile acid transport (LBAT) inhibitory activity. The invention also relates to pharmaceutical compositions comprising these compounds and to the use of these compounds in the treatment of cardiovascular diseases, fatty acid metabolism and glucose utilization disorders, gastrointestinal diseases and liver diseases.

Abstract: The present invention involves a novel method for treatment of chronic kidney disease comprising administering a compound that induces a stress protein response in a patient, and administering a potent antioxidant if the patent's response is below a predefined level. It also involves a quantitative measure for determining a patient's antioxidant reserve capacity.

Abstract: A 1-cyclopropyl-6-fluoro-4-oxo-7-(4-((2-thioxobenzo[d]thiazol-3(2H)-1-3-carboxylic acid compound, its synthesis, and its use as an antimicrobial agent.

Abstract: Borylated Amino Acid compositions comprising tyrosine derivatives BTS and BTS(OMe) and novel methods of making BTS and BTS(OMe) are disclosed herein. Consequently, the BTS and/or BTS(OMe) can be scaled up to commercial scale and administered to patients as a Neutron Capture Agent and provide a method of treating cancer, immunological disorders, and other disease by utilizing a Neutron Capture Therapy modality.

Abstract: Disclosed are a novel piperlongumine-based compound, an immuno regulator containing as an active ingredient the compound, or a pharmaceutically acceptable salt or solvate thereof, and a health functional food for immune regulation.

Abstract: A method for preparing an L-erythrobiopterin compound is provided. The L-erythrobiopterin compound has a structure represented by formula (I), and is mainly prepared from a compound having a structure represented by formula (II) or (III) through dihydroxylation. The preparation method of the L-erythrobiopterin compound is high in production efficiency, low in cost, environmentally friendly, and suitable for industrial production.

Abstract: A method for preparing FDCA with furfural as a raw material includes (1) pretreatment of the furfural: subjecting the furfural and an alcohol compound to an acetalization reaction under catalysis of an acidic ion resin to obtain an acetal compound of the furfural with the alcohol compound; (2) under stirring, adding the acetal compound dropwise to a mixed liquid of an acylation reagent and an ionic liquid (IL) to allow a reaction for 1 h to 2 h, adding a catalyst to continue the reaction for 3 h to 5 h, and subjecting a resulting reaction system to a post-treatment to obtain 5-acylfurfural; and (3) mixing the 5-acylfurfural with hydrogen peroxide, adding a catalyst to allow an oxidation reaction, and after the oxidation reaction is completed, subjecting a product to washing and recrystallization to obtain a white crystal, which is the FDCA.

Abstract: Provided herein is a method of forming a beta-lactone from a carboxylic acid having a beta-carbon with a hydrogen atom disposed thereon. The method comprises contacting a carboxylic acid of formula (1) as described herein with an effective amount of a palladium(II) catalyst, an effective amount of an N-protected aminoacid ligand, and t-butylhydroperoxide in a solvent comprising hexafluoroisopropanol (HFIP), at about 60° C. to provide a beta-lactone of formula (2) as described herein.

Abstract: The present invention is directed to a method for preventing and/or treating melanoma such as superficial spreading melanoma, nodular melanoma, lentigo maligna melanoma, and acral lentiginous melanoma. The method comprises administering to a subject in need thereof an effective amount of dapansutrile. The method optionally comprising co-administering anti-PD-1 antibody with dapansutrile. A preferred route of administration is oral administration.

Abstract: The present invention provides a novel crystalline form I of hydrochloride, a crystalline form II of hydrochloride, a crystalline form of succinate, a crystalline form of tartrate, a crystalline form I of fumarate and a crystalline form II of fumarate of 1-(5-(2,4-difluorophenyl)-1-((3-fluorophenyl)sulfonyl)-4-methoxy-1H-pyrrol-3-yl)-N-methylmethanamine. The above-described novel crystalline forms have high solubility in water and excellent stability under moisture-proof conditions and high-humidity exposure conditions, and thus can be pharmaceutically used.

Abstract: The present invention provides a compound having the structure: and use of the compound for inhibiting the growth of or killing

Abstract: The present disclosure relates to a novel boron-containing compound and an electrolyte additive for a secondary battery containing the same. An electrolyte for a secondary battery provided in one embodiment contains the novel boron-containing compound, such that decomposition of the electrolyte may be suppressed, thereby improving a capacity and a lifespan of the battery.

Abstract: Embodiments of the invention relate to the use of a melatonin agonist in the treatment of free running circadian rhythms in patients, including light perception impaired patients, e.g., blind patients, and to methods of measuring circadian rhythm.

Abstract: Provided are a novel boron-containing compound and an electrolyte solution additive for a secondary battery including the same. The electrolyte solution for a secondary battery provided in one embodiment includes the novel boron-containing compound, thereby suppressing the decomposition of an electrolyte solution to improve the capacity and the life characteristics of a battery.

Abstract: A method for preparing an acrylonitrile dimer according to the present disclosure makes it is possible to efficiently recover an acrylonitrile dimerization catalyst while reducing the process load.

Abstract: A method for synthesizing (RS)-Warfarin comprising preparing a liquid mixture, wherein the liquid mixture comprises trihexyltetradecylphosphonium bromide, methyl salicylate, acetyl chloride, benzaldehyde, and acetone. The method may further comprise incubating the liquid mixture at a temperature between 20° C. and 30° C. for a time duration between 26 and 34 minutes, and forming (RS)-Warfarin by adding water to the incubated liquid mixture with a volume ratio (water:incubated liquid mixture) between 1:1 and 1.5:1.

Abstract: The present invention relates to novel arginase inhibitors of formula (I). These novel compounds are useful in the treatment of diseases that are associated with arginase activity, such as asthma, allergic rhinitis and COPD (chronic obstructive pulmonary disease).

Abstract: The invention relates to N-(substituted-phenyl)-sulfonamide compounds, which are extremely useful as inhibitors of protein kinases (e.g. PERK kinase) and accordingly can be used for the treatment of cell proliferative disorders, such as cancer, or diseases associated with activated unfolded protein response pathways, such as Alzheimer's disease. The present invention also provides methods for preparing these compounds, pharmaceutical compositions comprising these compounds, and methods of treating diseases utilizing pharmaceutical compositions comprising these compounds.

Abstract: A compound of formula (I), or a salt thereof that may have an antagonistic action against an NMDA receptor that includes an NR2B subunit and may be useful as a prophylactic or therapeutic agent for depression, bipolar disorder, migraine, pain, a symptom peripheral to dementia, or the like.

Abstract: The present disclosure relates generally to LRRK2 inhibitors, or a pharmaceutically acceptable salt, deuterated analog, prodrug, tautomer, stereoisomer, or mixture of stereoisomers thereof, and methods of making and using thereof.